Acyclovir-loaded chitosan nanoparticles for ocular delivery

Rajendran N N, Natrajan R, Siva Kumar R, Selvaraj S

Abstract


The topical application of acyclovir as eye ointment remains a concern for effective management of various ocular viral diseases owing to poor ocular drug bioavailability. Hence the present study was aimed to develop and evaluate
nanosphere colloidal suspension containing acyclovir as potential ophthalmic drug delivery system. The acyclovir-loaded chitosan nanoparticles were prepared by ionic gelation of chitosan with tripolyphosphate anions. The nanoparticles were
characterized by scanning electron microcopy, zeta potential analyser, differential scanning calorimetry (DSC) and Fourier transform infrared Spectroscopy. All the prepared formulations resulted in nano-range size particles (200-495 nm) and
displayed spherical smooth morphology with zeta potential (+36.7 to +42.3 mV).The encapsulation efficiency and loading capacity were 56-80% and 10-25%, respectively. The acyclovir-loaded chitosan nanoparticles displayed more crystallinity than acyclovir. The in vitro diffusion profile of acyclovir from the nanoparticles showed a sustained release of the drug over a period of 24 hrs. Kinetic release profiles of acyclovir from nanoparticles appeared to fit best with Higuchi model with zero order and the non-Fickian diffusion was superior phenomenon. Thus the results suggest that acyclovir-loaded chitosan
nanoparticle suspension appears to be promising enough for effective management of ocular viral infections.


Full Text:

PDF

References


Jabs DA. Acyclovir for recurrent herpes simplex virus ocular disease. N

Engl J Med 1998;339:300-6.

Ohashi Y. Treatment of herpetic keratitis with acyclovir: Benefits and

problems. Ophthalmologica 1997;211:29-32.

Aylward GW, Claoue CM, Marsh RJ, Yasseem N. Influence of oral

acyclovir on ocular complications of herpes zoster ophthalmicus. Eye

;8:70-4.

Pavan-Langston D. Herpetic infections. In: Smolin G, Thoft RA, editors.

The Cornea, 3rd ed. Boston, Massachusetts: Little Brown; 1994. p.

-214.

Taskintuna I, Banker AS, Flores-Aguilar M, Bergeron-Lynn G, Aldern KA,

Hostetler KY, et al. Evaluation of a novel lipid prodrug for intraocular

drug delivery: Effect of acyclovir diphosphate dimyristoylglycerol in a

rabbit model with herpes simplex virus-1 retinitis. Retina 1997;17:57-64.

Genta I, Conti B, Perugini P, Pavanetto F, Spadaro A, Puglisi G.

Bioadhesive microspheres for ophthalmic administration of acyclovir.

J Pharma Pharmacol 1997;49:737-42.

Calvo P, Alonso MJ, Vila-Yato JL, Robinson JR. Improved ocular

bioavailability of indomethacin by novel oculardrug carriers. J Pharm

Pharmacol 1996;48:1147-52.

De Campos M, Sanchez A, Alonso MJ. Chitosan nanoparticles: A new

vehicle for the improvement of the delivery of drugs to the ocular

surface. Application to cyclosporin A. Int J Pharm 2001;224:159-68.

Knapczyk J, Kro ́wczynski L, Krzck J, Brzeski M, Nirnberg E, Schenk

D, et al. Requirements of chitosan for pharmaceutical and biomedical

applications. In: Skak-Braek G, Anthonsen T, Sandford P, editors. Chitin

and Chitosan: Sources, Chemistry, Biochemistry, Physical Properties

and Applications. London: Elsevier; 1989. p. 657-63.

Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the

permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm

Res 1994;11:1358-61.

Giannavola C, Bucolo C, Maltese A, Paolino D, Vandelli MA, Puglisi G,

et al. Influence of preparation conditions on acyclovir-loaded poly-

d,l-lactic acid nanospheres and effect of PEG coating on ocular drug

bioavailability. Pharma Res 2003;20:584-90.

de Campos AM, Diebold Y, Carvalho EL, Sánchez A, Alonso MJ. Chitosan

nanoparticles as new ocular drug delivery systems: In vitro Stability,

in vivo fate, and cellular toxicity. Pharm Res 2004;21:803-10.

Enríquez de Salamanca A, Diebold Y, Calonge M, García-Vazquez C,

Callejo S, Vila A, et al. Chitosan nanoparticles as a potential drug delivery

system for the ocular surface: Toxicity, uptake mechanism and in vivo

tolerance. Invest Ophthalmol Vis Sci 2006;47:1416-25.

Lurui Qin Zhu Wall. Acyclovir chitosan nanoparticles in rabbit’s eyes.

Pharm Clin Res 2007;15:1.

Calvo P, Vila-Jato JL, Alonso MJ. Evaluation of cationic polymer-coated

nanocapsules as ocular drug carriers. Int J Pharm 1997a;53:41-50.

Yadav KS, Sathish CS, Shivkumar HG. Preparation and evaluation of

chitosan –Poly(Acrylic acid)Hydrogels as stomach specific delivery

for amoxicillin and metronidazole. Indian J Pharm Sci 2007;69:91-5.

Alonso MJ, Sanchez A. Biodegradable nanoparticles as new transmucosal drug carrier. Carrier Based Drug Delivery 2004;879:283-95.

Lehr CM, Bouwstra JA, Schacht EH, Junginger HE. Invitro evaluation of

mucoadhesive properties of chitosan and some other natural polymers.

Int J Pharm 1992;78:43-8.

Feltt O, Buri P, Gurny R. Chitosan; a unique polysaccharide for drug

delivery. Drug Dev Ind Pharm 1998;24:979-93.

Desai MP, Labhasetwar V, Amidon GL Levy RJ. Gastrointestinal uptake

of biodegradable microparticles: Effect of particle size. Pharmacol Res

;13:1838-45.

Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Novel hydrophilic

chitosan–polyethylene oxide nanoparticles as protein carriers. J Appl

Polm Sci 1997b;63:125-32.

Mosqueira VC, Legrand P, Gref R, Barratt G. In-vitro release kinetic

studies of PEG-modified nanocapsules and nanospheres loaded

with a lipophilic drug: Halofantrine base. Control Rel Bioact Mater

;26:1074-5.

Mosqueira VC, Legrand P, Pinto-Alphandary H, Puisieux F, Barratt G. Poly(D, L-lactide) nanocapsules prepared by a solvent displacement process:Influence of the composition on physicochemical and structural

properties. J Pharm Sci 2000;89:614-26.

Wu Y, Yang W, Wang C, Hu J, Fu S. Chitosan nanoparticles as a

novel delivery system for ammonium glycyrrhizinate. Int J Pharm

;295:235-45.

Zhou SB, Deng XM, Li X. Investigation on a novel core-coated

microspheres protein delivery system. J Control Release 2001;75:27-36.

Fernandez-Urrusuno R, Calvo P, Remunan-Lopez C, Vila-Jato JL,

Alsono MJ. Enhancement of nasal absorption of insulin using chitosan

nanoparticles. Pharm Res 1999;16:1576-81.

Lehr CM, Bouwstra JA, Schacht E, Junginger HE. In vitro evaluation of

mucoadhesive properties of chitosan and some other natural polymers.

Int J Pharm 1992;78:43-8.

Gundu ZK, O Zdemir O. Topical cyclosporine treatment of

keratoconjunctivitis sicca in secondary Sjogren’s syndrome. Acta

Ophthalmol 1994;72:438-42.




DOI: http://dx.doi.org/10.22377/ajp.v4i4.290

Refbacks

  • There are currently no refbacks.